Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B
Phase 3
Completed
- Conditions
- Chronic Hepatitis B
- Registration Number
- NCT00131742
- Lead Sponsor
- Novartis
- Brief Summary
This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Documented clinical history compatible with chronic hepatitis B infection
Other protocol-defined inclusion criteria may apply
Exclusion Criteria
- Patient is pregnant or breastfeeding
- Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or HIV
- Patient has previously received lamivudine or any investigational anti-HBV nucleoside or nucleotide analog
Other protocol-defined exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method